ROGER A GREENBERG

Dr. ROGER A GREENBERG

Cancer Biology, Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Mississippi, USA
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
SHShane M. Harding
Shane M. Harding
JBJoseph L. Benci
Joseph L. Benci
JIJerome Irianto
Jerome Irianto
DDDennis E. Discher
Dennis E. Discher
AMAndy J. Minn
Andy J. Minn
RGROGER A GREENBERG
ROGER A GREENBERG
The authors report a link between mitosis, the formation of micronuclei and DNA-damage-induced cGAS-dependent inflammation. Ionizing radiation and genotoxic cancer therapy induce innate immunity mechanisms and lead to an increased production of inflammatory cytokines. The delayed nature of this response, which occurs a few days after treatment, is not well understood. Roger Greenberg and colleagues report a link between mitosis, the formation of micronuclei and DNA-damage-induced inflammatory signalling involving the pattern recognition receptor cGAS in cancer cells. The authors advise that temporal modulation of the cell cycle is important to consider in therapeutic approaches involving genotoxic agents and immune checkpoint blockers. Elsewhere in this issue, Andrew Jackson and colleagues provide evidence for an underlying mechanism whereby ruptured micronuclei activate a cell-autonomous inflammatory response via cGAS. Inflammatory gene expression following genotoxic cancer therapy is well documented, yet the events underlying its induction remain poorly understood. Inflammatory cytokines modify the tumour microenvironment by recruiting immune cells and are critical for both local and systemic (abscopal) tumour responses to radiotherapy1. A poorly understood feature of these responses is the delayed onset (days), in contrast to the acute DNA-damage responses that occur in minutes to hours. Such dichotomous kinetics implicate additional rate-limiting steps that are essential for DNA-damage-induced inflammation. Here we show that cell cycle progression through mitosis following double-stranded DNA breaks leads to the formation of micronuclei, which precede activation of inflammatory signalling and are a repository for the pattern-recognition receptor cyclic GMP–AMP synthase (cGAS). Inhibiting progression through mitosis or loss of pattern recognition by stimulator of interferon genes (STING)–cGAS impaired interferon signalling. Moreover, STING loss prevented the regression of abscopal tumours in the context of ionizing radiation and immune checkpoint blockade in vivo. These findings implicate temporal modulation of the cell cycle as an important consideration in the context of therapeutic strategies that combine genotoxic agents with immune checkpoint blockade.

25 May 2007 in Science
Verified
Journal Article
Closed access
PDF file
BSBijan Sobhian
Bijan Sobhian
GSGenze Shao
Genze Shao
DLDana R. Lilli
Dana R. Lilli
ACAedín C. Culhane
Aedín C. Culhane
LMLisa A. Moreau
Lisa A. Moreau
RGROGER A GREENBERG
ROGER A GREENBERG
Mutations affecting the BRCT domains of the breast cancer–associated tumor suppressor BRCA1 disrupt the recruitment of this protein to DNA double-strand breaks (DSBs). The molecular structures at DSBs recognized by BRCA1 are presently unknown. We report the interaction of the BRCA1 BRCT domain with RAP80, a ubiquitin-binding protein. RAP80 targets a complex containing the BRCA1-BARD1 (BRCA1-associated ring domain protein 1) E3 ligase and the deubiquitinating enzyme (DUB) BRCC36 to MDC1-γH2AX–dependent lysine 6 - and lysine 63 -linked ubiquitin polymers at DSBs. These events are required for cell cycle checkpoint and repair responses to ionizing radiation, implicating ubiquitin chain recognition and turnover in the BRCA1-mediated repair of DSBs.

3 February 2013 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JTJiangbo Tang
Jiangbo Tang
NCNam Woo Cho
Nam Woo Cho
GCGaofeng Cui
Gaofeng Cui
EMErica M Manion
Erica M Manion
NSNiraj M Shanbhag
Niraj M Shanbhag
RGROGER A GREENBERG
ROGER A GREENBERG
Competitive binding of 53BP1 and BRCA1 determines DNA repair pathway choice at double-strand breaks. New work shows that acetylation of H4K16 by TIP60 tips the balance in favor of BRCA1 by limiting 53BP1 binding, thereby promoting repair through homologous recombination over nonhomologous end joining. The pathogenic sequelae of BRCA1 mutation in human and mouse cells are mitigated by concomitant deletion of 53BP1, which binds histone H4 dimethylated at Lys20 (H4K20me2) to promote nonhomologous end joining, suggesting that a balance between BRCA1 and 53BP1 regulates DNA double strand–break (DSB) repair mechanism choice. Here we document that acetylation is a key determinant of this balance. TIP60 acetyltransferase deficiency reduced BRCA1 at DSB chromatin with commensurate increases in 53BP1, whereas HDAC inhibition yielded the opposite effect. TIP60-dependent H4 acetylation diminished 53BP1 binding to H4K20me2 in part through disruption of a salt bridge between H4K16 and Glu1551 in the 53BP1 Tudor domain. Moreover, TIP60 deficiency impaired homologous recombination and conferred sensitivity to PARP inhibition in a 53BP1-dependent manner. These findings demonstrate that acetylation in cis to H4K20me2 regulates relative BRCA1 and 53BP1 DSB chromatin occupancy to direct DNA repair mechanism.

19 October 2016 in Nature
Verified
Journal Article
Closed access
PDF file
RDRobert L. Dilley
Robert L. Dilley
PVPriyanka Verma
Priyanka Verma
NCNam Woo Cho
Nam Woo Cho
HWHarrison D. Winters
Harrison D. Winters
AWAnne R. Wondisford
Anne R. Wondisford
RGROGER A GREENBERG
ROGER A GREENBERG

1 September 2014 in Cell
Verified
Journal Article
Closed access
NCNam Woo Cho
Nam Woo Cho
RDRobert L. Dilley
Robert L. Dilley
MLMichael A. Lampson
Michael A. Lampson
RGROGER A GREENBERG
ROGER A GREENBERG

1 February 2015 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SSSarah L. Sawyer
Sarah L. Sawyer
LTLei Tian
Lei Tian
MKMarketta Kähkönen
Marketta Kähkönen
JSJeremy Schwartzentruber
Jeremy Schwartzentruber
MKMartin Kircher
Martin Kircher
RGROGER A GREENBERG
ROGER A GREENBERG
Deficiency in BRCA-dependent DNA interstrand crosslink (ICL) repair is intimately connected to breast cancer susceptibility and to the rare developmental syndrome Fanconi anemia. Bona fide Fanconi anemia proteins, BRCA2 (FANCD1), PALB2 (FANCN), and BRIP1 (FANCJ), interact with BRCA1 during ICL repair. However, the lack of detailed phenotypic and cellular characterization of a patient with biallelic BRCA1 mutations has precluded assignment of BRCA1 as a definitive Fanconi anemia susceptibility gene. Here, we report the presence of biallelic BRCA1 mutations in a woman with multiple congenital anomalies consistent with a Fanconi anemia–like disorder and breast cancer at age 23. Patient cells exhibited deficiency in BRCA1 and RAD51 localization to DNA-damage sites, combined with radial chromosome formation and hypersensitivity to ICL-inducing agents. Restoration of these functions was achieved by ectopic introduction of a BRCA1 transgene. These observations provide evidence in support of BRCA1 as a new Fanconi anemia gene (FANCS). Significance: We establish that biallelic BRCA1 mutations cause a distinct FA-S, which has implications for risk counselling in families where both parents harbor BRCA1 mutations. The genetic basis of hereditary cancer susceptibility syndromes provides diagnostic information, insights into treatment strategies, and more accurate recurrence risk counseling to families. Cancer Discov; 5(2); 135–42. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 97